Investigational drug for treatment of advanced Non-Small Cell Lung Cancer

Trial ID:
Michael P. Kosty, M.D.
This study will test the safety of an investigational oral drug, BBP-398, combined with an FDA approved dose of Nivolumab. The purpose of this Phase I study is to find a safe dose range of BBP-398 that can be given to patients with non-small cell lung cancer.

Inclusion Criteria

Patients must:
  • Be 18 years or older
  • Have documentation of a KRAS mutation
  • Be willing to record daily intake of study drug in diary
  • Be able to swallow oral medication

Exclusion Criteria

Patients must not:
  • Have history of significant cardiovascular disease
  • Have undergone major surgery within 4 months of starting treatment
  • Have a history of allogenic bone marrow transplant

Additional Info

  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion).
  • Search NCT05375084 at website for more information.

Contact Info:

  • Clinical Research Services